Early Curative Applications of the Aminoglycoside WR279396 on an ExperimentalLeishmania major-Loaded Cutaneous Site Do Not Impair the Acquisition of Immunity
- 1 March 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (3) , 984-990
Abstract
Topical therapy is an attractive approach for the treatment ofLeishmaniamajorcutaneous leishmaniasis (CL). WR279396, an expanded-spectrum aminoglycoside ointment, is now in phase 3 trials. Because the application of a cream is easier than the injection of pentavalent antimony, many patients with CL will likely be treated with WR279396 soon after the onset of a lesion. However, this new therapeutic approach may impair the acquisition of immunity. We evaluated the impact of early topical therapy on acquired immunity in an optimized mouse model ofL. major-induced CL. The efficacy of the WR279396 ointment in this model has been established previously. Acquired immunity was defined as the absence of lesions upon reinoculation of the same parasite isolate at a different skin site. Bioluminescence-based follow-up of luciferase-expressingL. majorloads was also performed. In this model, the control ofL. majorloads at the initial inoculation site and the acquisition of immunity are simultaneous (day 22 postinoculation). The clinical and parasitological efficacies of WR279396 applied as early as day 11 postinoculation, i.e., during theL. majormultiplication phase, did not impair the acquisition of immunity to a secondL. majorchallenge. This is reassuring from the perspective of the wide deployment of WR279396-based therapy in foci whereL. majoris endemic.Keywords
This publication has 26 references indexed in Scilit:
- WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled StudyPLOS Neglected Tropical Diseases, 2009
- Optimization of Topical Therapy for Leishmania major Localized Cutaneous Leishmaniasis Using a Reliable C57BL/6 ModelPLOS Neglected Tropical Diseases, 2007
- Perturbation of the Dimer Interface of Triosephosphate Isomerase and its Effect on Trypanosoma cruziPLOS Neglected Tropical Diseases, 2007
- Detection and Identification ofLeishmaniaSpecies from Clinical Specimens by Using a Real-Time PCR Assay and Sequencing of the CytochromebGeneJournal of Clinical Microbiology, 2007
- Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006Kinetoplastid Biology and Disease, 2007
- Immunization with Persistent Attenuated Δ lpg2 Leishmania major Parasites Requires Adjuvant To Provide Protective Immunity in C57BL/6 MiceInfection and Immunity, 2006
- Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living miceCellular Microbiology, 2004
- Role for CD4+ CD25+ Regulatory T Cells in Reactivation of Persistent Leishmaniasis and Control of Concomitant ImmunityJournal of Experimental Medicine, 2004
- CD4+CD25+ regulatory T cells control Leishmania major persistence and immunityNature, 2002
- Limiting dilution assaysJournal of Immunological Methods, 1987